Mary C. Beckerle Sells 12,210 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Exelixis Stock Performance

Shares of Exelixis stock opened at $35.09 on Friday. The firm has a fifty day moving average of $34.16 and a two-hundred day moving average of $31.14. The stock has a market capitalization of $9.82 billion, a price-to-earnings ratio of 19.82, a PEG ratio of 1.10 and a beta of 0.53. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Institutional Trading of Exelixis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Forum Financial Management LP bought a new stake in shares of Exelixis during the 4th quarter valued at $241,000. GF Fund Management CO. LTD. acquired a new position in shares of Exelixis in the 4th quarter valued at $200,000. Neo Ivy Capital Management grew its holdings in shares of Exelixis by 427.8% in the 4th quarter. Neo Ivy Capital Management now owns 53,892 shares of the biotechnology company’s stock valued at $1,794,000 after buying an additional 43,682 shares during the period. JT Stratford LLC acquired a new position in shares of Exelixis in the 4th quarter valued at $288,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Exelixis by 4.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 844,345 shares of the biotechnology company’s stock valued at $28,117,000 after buying an additional 33,804 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of research analyst reports. BMO Capital Markets cut shares of Exelixis from an “outperform” rating to a “market perform” rating and lifted their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. Citigroup lifted their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Stifel Nicolaus lifted their target price on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 target price on shares of Exelixis in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.24.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.